Researchers are investigating whether popular weight-loss medications could help preserve memory and thinking skills.
Obesity medications and those prescribed for type 2 diabetes may have benefits that extend beyond weight management and blood sugar control. Researchers are now examining whether these treatments could also help protect memory, attention, and other mental abilities as people age. A review published in the journal Science explores the growing evidence and considers how these medications might contribute to future treatments for conditions affecting the brain.
The review was prepared by researchers affiliated with the University of Gothenburg in Sweden and the University of Copenhagen in Denmark. Their work focuses on a group of obesity medications known as GLP-1 drugs, which includes semaglutide and tirzepatide. These medicines are already widely used to help people manage obesity and type 2 diabetes. However, scientists are becoming increasingly interested in how they affect other systems in the body, including those involved in brain health.
Research involving animals has found that GLP-1 medications can influence learning and memory. Results from studies involving people, however, have not been as consistent. Some research examining medical records has found that people with type 2 diabetes who received GLP-1 treatment appeared to have a lower risk of developing dementia. These findings are encouraging, but they do not prove that the medications directly prevent dementia. Other factors affecting the patients’ health could help explain the differences.
Clinical trial results have also raised questions about how much protection these drugs may offer against specific brain diseases. In two studies known as EVOKE and EVOKE+, semaglutide was tested in people with early-stage Alzheimer’s disease. The medication did not slow the progression of the disease, even though researchers observed changes in several biological markers associated with Alzheimer’s. This means that the treatment did not produce the expected improvement in disease progression during those trials.
Researchers say these findings do not necessarily mean the medications lack benefits for other groups of people. Individuals living with obesity or type 2 diabetes can experience problems with attention, planning, and the speed at which they process information. These difficulties may be connected to metabolic problems and changes in blood vessel health. Because GLP-1 medications can improve aspects of metabolic health, scientists want to determine whether treating these conditions could also help preserve mental abilities.
Stina Börchers, the review’s first author and a researcher affiliated with both universities, said more research is needed to determine whether people with obesity or diabetes can maintain their cognitive abilities through treatment. One question is whether starting medication before noticeable memory or thinking problems develop could make a difference. Researchers also want to understand which patients are most likely to benefit.
Another area of investigation involves determining how these medications affect the brain. Their influence could come from improvements in blood sugar control, body weight, and other metabolic processes. They might also have more direct effects on brain cells and the systems responsible for memory and learning. It is possible that both pathways contribute to any benefits observed.
Christoffer Clemmensen, senior author of the review and a research group leader at the University of Copenhagen, said advances in obesity medications are creating new opportunities to study the relationship between metabolism and brain function. Understanding how the treatments work could eventually help scientists develop medicines designed specifically to preserve cognitive abilities.
The researchers are calling for clinical trials that measure memory and other thinking skills from the beginning of treatment. Following participants over time would help determine whether changes in cognitive performance are connected to the medication and whether certain groups experience greater benefits.
They also caution that treatment needs to be carefully monitored in older adults and people who are physically frail. Losing weight too quickly or losing too much muscle can reduce strength and interfere with everyday activities. These effects could limit any possible advantages for brain health.
For now, GLP-1 medications should not be considered proven treatments for preventing dementia or slowing Alzheimer’s disease. The review instead points to questions that future research needs to answer. Scientists hope that a clearer understanding of the relationship between metabolic health and the brain will eventually lead to better ways of protecting memory and mental function.
Sources:
Obesity drugs may help protect memory and cognitive abilities
Join the conversation!